Last Update 22 Jun 26

OMCL: Earnings Rebound And Guidance Will Support Higher Future Earnings Multiple

Analysts have nudged their price targets on Omnicell higher, with recent Street research pointing to modestly improved expectations that support a slightly richer long term fair value framework anchored around $55.

Analyst Commentary

Recent Street research on Omnicell reflects a mixed tone, with higher price targets framed within a cautious backdrop. While headline target moves point to somewhat firmer confidence around a long term value near US$55, several comments highlight that execution and growth expectations still carry meaningful uncertainty.

Bearish analysts are using the occasion of these price target revisions to flag that Omnicell may have limited room for error if it falls short on growth, margin progress or pipeline conversion, even if the current valuation appears more balanced than before.

Bearish Takeaways

Bearish analysts caution that the higher price targets are still anchored close to prior ranges. They see this as a signal that Omnicell’s valuation already reflects a lot of the anticipated improvement in its business.
Some commentary highlights the risk that if Omnicell’s revenue trajectory or cost controls do not track current assumptions, the current fair value framework around US$55 could prove demanding relative to execution.
There is concern that any delay in growth initiatives or slower than expected adoption of Omnicell’s offerings could lead to renewed pressure on estimates. Bearish analysts see this as a constraint on upside potential.
Bearish analysts also point to the possibility that competitive or operational challenges could limit Omnicell’s ability to expand margins. This could in turn cap how far valuation multiples can stretch from here.

What’s in the News for Omnicell

Omnicell is featured in recent research highlighting a hammer chart pattern that some technical analysts view as a sign of share price support, with the stock covered as Zacks Rank #1 (Strong Buy) and commentary citing a consensus view of roughly 40.6% potential upside alongside earnings estimate revisions higher. Source: Zacks, TipRanks, Craig Hallum.
Analysts in the same coverage reiterate positive views on Omnicell’s earnings outlook, pointing to a series of upward revisions to earnings estimates and ongoing buy ratings that keep the stock on the radar for investors focused on earnings quality. Source: Zacks, TipRanks, Craig Hallum.
Omnicell provided earnings guidance for full year 2026, with total revenues expected in a range of US$1.215b to US$1.255b. This gives investors a clearer view of management’s current top line assumptions for the year. Source: company guidance.
For the second quarter of fiscal 2026, Omnicell issued revenue guidance in a range of US$307m to US$313m. This adds more detail around shorter term expectations that investors can compare with Street models. Source: company guidance.
Omnicell initiated a voluntary Class I recall related to specific lots of sterile label stock used with the Omnicell i.v.STATION device, citing a risk of mislabeled syringes, with approximately 220 units affected and distribution in Alabama, Maryland and Pennsylvania. Source: US FDA recall notice.

Valuation Changes for Omnicell

Fair Value: Modelled fair value for Omnicell remains unchanged at $55.0. This indicates no shift in the central price anchor used in this framework.
Discount Rate: The discount rate has fallen slightly from 8.01% to 7.66%. This generally implies a modestly lower required return being applied to future cash flows.
Revenue Growth: The revenue growth assumption has risen slightly from 3.62% to 3.83%. This reflects a small upward adjustment to Omnicell’s projected top line pace.
Net Profit Margin: The profit margin assumption has moved up slightly from 5.75% to 5.98%. This points to a marginally higher expected level of earnings efficiency on future revenue.
Future P/E: The future P/E multiple has edged higher from 36.26x to 36.85x. This suggests a small increase in the valuation multiple applied to Omnicell’s expected earnings.

0 views

Key Takeaways

Increasing cost pressures, buyer consolidation, and commoditization are compressing margins and eroding Omnicell's pricing power and market leadership.
Heightened regulatory and cybersecurity demands, alongside cloud model transition risks, threaten profit growth and long-term competitive positioning.
Transitioning to a tech-enabled, recurring revenue model with strong product demand, resilient supply chain, industry certifications, and robust customer pipeline supports sustained growth and margin improvement.

Catalysts

About Omnicell

Provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally.What are the underlying business or industry changes driving this perspective?

Growing government cost-containment measures and increasing pressure to reduce healthcare spending are expected to limit capital budgets for Omnicell's largest customers, reducing upgrade cycles and new system installations, and ultimately constraining top line growth over the next several years.
As hospital systems and pharmacy providers accelerate consolidation and digital transformation, negotiating leverage will increasingly shift toward large integrated buyers, driving aggressive pricing demands and compressing Omnicell's gross and net margins, especially as technology solutions become seen as commodities rather than differentiated products.
Rising cybersecurity costs and ever-evolving regulatory compliance burdens, especially with heightened scrutiny for cloud-based clinical systems and increased cyber risk exposure, will require sustained, higher R&D and operational spending, diminishing profitability and threatening Omnicell's competitive edge in cloud and SaaS offerings.
Execution risk in transitioning to a SaaS and cloud-centric recurring revenue model may lead to slower adoption than projected, higher-than-expected customer churn, and unfulfilled revenue projections, particularly if health systems delay or reduce IT spending during economic downturns or face internal integration challenges.
Intensifying competition from diversified automation and analytics providers, combined with rapid commoditization of medication management technology, threatens both revenue growth and long-term pricing power, putting Omnicell's leadership position and future earnings at risk as they become less differentiated and increasingly vulnerable to market share losses.

Omnicell Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

This narrative explores a more pessimistic perspective on Omnicell compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
The bearish analysts are assuming Omnicell's revenue will grow by 3.8% annually over the next 3 years.
The bearish analysts assume that profit margins will increase from 1.7% today to 6.0% in 3 years time.
The bearish analysts expect earnings to reach $82.0 million (and earnings per share of $1.78) by about June 2029, up from $20.4 million today. The analysts are largely in agreement about this estimate.
In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 37.0x on those 2029 earnings, down from 86.9x today. This future PE is greater than the current PE for the US Medical Equipment industry at 24.4x.
The bearish analysts expect the number of shares outstanding to decline by 0.99% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.66%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Omnicell's ongoing transition from a device-centric model to a tech-enabled, platform-based business-with strong growth in recurring revenues via SaaS, cloud subscriptions, and Advanced Services-supports greater revenue visibility and margin improvement over the long term, evidenced by a growing predictable recurring revenue base now around 50 percent of the business.
Continued strong customer demand across inpatient and outpatient settings, alongside successful new product launches such as OmniSphere, MedVision, and MedTrack, has driven all-time-high product bookings and record installed base growth, indicating potential for sustained revenue and earnings expansion as enterprise healthcare customers adopt these integrated automation and analytics solutions.
The company is making significant progress in mitigating tariff and supply chain risks, including resilient supply chain efforts and successful implementation of price increases with a pleased market reception, which supports gross margin stability and protects profit margins as cost pressures ease into 2026.
Securing industry certifications like HITRUST for its cloud platform and maintaining a leadership position in cybersecurity and regulatory compliance strengthens Omnicell's value proposition with large health systems, enhancing customer retention and supporting stable top-line growth and higher net margins.
The robust product pipeline and customer wins-including exclusive partnerships in IV automation and central pharmacy dispensing, alongside high visibility into implementation schedules-suggest strong forward revenue commitments into next year, reinforcing expectations for stable to rising earnings and free cash flow despite macroeconomic uncertainty.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bearish price target for Omnicell is $55.0, which represents up to two standard deviations below the consensus price target of $61.29. This valuation is based on what can be assumed as the expectations of Omnicell's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $70.0, and the most bearish reporting a price target of just $55.0.
In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $1.4 billion, earnings will come to $82.0 million, and it would be trading on a PE ratio of 37.0x, assuming you use a discount rate of 7.7%.
Given the current share price of $39.05, the analyst price target of $55.0 is 29.0% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Omnicell?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Government Cost Containment And Cybersecurity Burdens Will Impair Margins